Hiv: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797441
  • Drug Pipelines
  • 455 pages
  • Datamonitor Healthcare
1 of 3
Despite the anticipated launch of generics of blockbuster brands, an increase in HIV prevalence and continued uptake of premium single-tablet regimens (STRs) will drive continued market growth during 2015-24.

This report addresses the following questions:

- Which brands will drive further growth in the HIV market during 2015-24, and why?
- How successful have Triumeq’s and Tivicay’s launches been and where are they currently positioned in the treatment algorithm?
- What are physicians’ views on the breaking up of fixed-dose combinations to prescribe cheaper separate generic components?
- What percentage of diagnosed patients are currently under medical care and receiving antiretroviral therapy?
- How will recent updates to US and EU treatment guidelines affect prescribing patterns in newly diagnosed patients?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: HIV

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Brand Forecasts
- Atripla
- Complera
- D/C/F/TAF
- Epzicom
- fostemsavir
- F/TAF
- Genvoya
- Isentress
- Prezista franchise
- Reyataz franchise
- R/F/TAF
- Stribild
- Tivicay
- Triumeq
- Truvada
- Primary Research Methodology

TREATMENT: HIV

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in HIV
- Impact of Generics

EPIDEMIOLOGY: HIV

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: HIV

- Executive Summary
- Product Overview
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll